Eli Lilly Raises 2026 Sales Forecast as GLP-1 Obesity Drug Demand Surges
Eli Lilly raised its full-year 2026 sales forecast as demand for obesity and diabetes drugs continues to surge
Key points
- Eli Lilly raises 2026 sales forecast on surging GLP-1 obesity and diabetes drug demand
- Novo Nordisk faces increased competitive pressure as Lilly scales manufacturing
- Watch Q4 Zepbound prescription data and CMS reimbursement decisions for demand catalysts
Does this change your view on the stock? Share your take below.
Read the full analysis on market.news
🌐 Global Stocks Earnings pharma healthcare guidance-raise